As we better understand the biology of individual breast cancers and can personalize treatment, pathologic complete responses (pCR) have become more common especially with utilizing dual HER2-directed therapy in HER2-positive breast cancer patients and the use of pembrolizumab, an immune checkpoint inhibitor in triple-negative breast cancer patients in a neoadjuvant setting [18,19]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.